PTC Free cash flow increased by 19.0% to $318.25M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $278.50M to $318.25M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 25.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $84.61M | $32.27M | $134.37M | $140.18M | $112.30M | $28.98M | $171.74M | $207.18M | $164.14M | $43.99M | $182.78M | $247.09M | $212.16M | $93.58M | $235.66M | $278.50M | $242.04M | $100.48M | $267.40M | $318.25M |
| QoQ Change | — | -61.9% | +316.4% | +4.3% | -19.9% | -74.2% | +492.6% | +20.6% | -20.8% | -73.2% | +315.5% | +35.2% | -14.1% | -55.9% | +151.8% | +18.2% | -13.1% | -58.5% | +166.1% | +19.0% |
| YoY Change | — | — | — | — | +32.7% | -10.2% | +27.8% | +47.8% | +46.2% | +51.8% | +6.4% | +19.3% | +29.3% | +112.7% | +28.9% | +12.7% | +14.1% | +7.4% | +13.5% | +14.3% |